March 21, 2024

The U.S. Food and Drug Administration (FDA) published a paper March 15, to update the public about intra-agency activities to oversee artificial intelligence (AI)-enabled healthcare technologies. The paper summarizes priorities shared across the biologics, drugs and medical devices domains of FDA jurisdiction.

Four general focus areas are discussed: fostering collaboration with stakeholders; developing appropriate regulatory approaches; promoting development of standards and best practices; and supporting research on performance evaluation. Moving forward, the FDA intends to evolve its own regulatory approaches with the continued progression of AI tools.

For more information about various American College of Radiology®(ACR®) AI-specific initiatives, visit the ACR Data Science Institute®. For more information about FDA oversight and digital health policy, contact Michael Peters, ACR Senior Government Affairs Director.


Related ACR News

  • ACR Drives Urgency For Medicare Pay Fix in Senate Bill

    ACR highlighted the urgent need for a permanent Medicare physician pay fix in a June 23 letter to U.S. Senate leaders.

    Read more
  • ACR Urges Senate to Reconsider Student Loan Program Changes

    ACR and other medical groups cautioned that the student loan provisions would make medical and dental education less accessible to many qualified individuals.

    Read more
  • CMS Releases NCCI Quarterly Edit Files

    The Centers for Medicare and Medicaid Services released the quarterly National Correct Coding Initiative Procedure-to-Procedure edits, effective Oct. 1.

    Read more